Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Income towards Parent Company: 2019-2024

Historic Income towards Parent Company for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to -$160.8 million.

  • 4D Molecular Therapeutics' Income towards Parent Company fell 29.68% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.1 million, marking a year-over-year decrease of 45.83%. This contributed to the annual value of -$160.8 million for FY2024, which is 59.74% down from last year.
  • As of FY2024, 4D Molecular Therapeutics' Income towards Parent Company stood at -$160.8 million, which was down 59.74% from -$100.7 million recorded in FY2023.
  • In the past 5 years, 4D Molecular Therapeutics' Income towards Parent Company registered a high of -$56.5 million during FY2020, and its lowest value of -$160.8 million during FY2024.
  • In the last 3 years, 4D Molecular Therapeutics' Income towards Parent Company had a median value of -$107.5 million in 2022 and averaged -$123.0 million.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Income towards Parent Company increased by 6.33% in 2023, and later crashed by 59.74% in 2024.
  • 4D Molecular Therapeutics' Income towards Parent Company (Yearly) stood at -$56.5 million in 2020, then dropped by 25.98% to -$71.2 million in 2021, then slumped by 50.93% to -$107.5 million in 2022, then increased by 6.33% to -$100.7 million in 2023, then crashed by 59.74% to -$160.8 million in 2024.